Female Breast Cancer Clinical Trial
Official title:
Patients' Preferences for Adjuvant or Neoadjuvant Chemotherapy in Breast Cancer
The aim of the present study is to ask women treated with adjuvant or neoadjuvant chemotherapy for breast cancer what survival benefit would justify the treatment. The benefit should be evaluated in terms of Survival rate trade off and Survival time trade off value. The analyses will be conducted into three different groups of patients to value the survival benefit expected: 1. before to start the chemotherapy 2. during chemotherapy 3. after the end of chemotherapy
The chemotherapy is generally proposed a large number of early breast cancer patients to reduce the risk of recurrence and death. However chemotherapy is associated with side effects that impact the quality of life of the patients. Patients are more likely to accept treatment on the basis of presented relative rather than absolute risks and so the question arises as to whether unrealistic improvements in outcome are expected by patients. The interviews with patients in the proposed trial will elicit the expected gains both in terms of survival and life years and will be able to assess the proportion of patients who considered an improvement of realistic size was sufficient to justify the treatment. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT02480933 -
Silent Breast Cancer A Study of the Disease Prevalence Held by Imaging Guided Biopsies in Autopsy Specimens
|
N/A | |
| Completed |
NCT05000502 -
Exercise, Gut Microbiome, and Breast Cancer: Increasing Reach to Underserved Populations
|
N/A | |
| Not yet recruiting |
NCT04863833 -
Tomosymthesis for Breast Mass Lesion Characterization
|
||
| Recruiting |
NCT06145399 -
A Study of 1 8F-FDHT PET/MRIScans in Women With Breast Cancer
|
Early Phase 1 | |
| Suspended |
NCT01320488 -
Breast Cancer in Young Women: Is it Different?
|
N/A | |
| Recruiting |
NCT02089854 -
Adjuvant Endocrine Therapy for Estrogen Receptor-beta Positive Triple Negative Breast Cancer
|
Phase 4 | |
| Active, not recruiting |
NCT01741883 -
Side Effect Prevention Training (SEPT) for Nocebo Effects in Breast Cancer Patients
|
N/A | |
| Recruiting |
NCT06144164 -
A Study of a Comprehensive Prevention Program to Reduce Lymphedema After Axillary Lymph Node Dissection in People With Breast Cancer
|
Phase 3 | |
| Recruiting |
NCT06331793 -
Pulsed Electromagnetic Fields for Analgesia Post Mastectomy
|
N/A | |
| Recruiting |
NCT05439499 -
This is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of FCN-437c Versus Placebo in Combination With Letrozole or Anastrozole ± Goserelin in Women With HR+ and HER2- Advanced Breast Cancer.
|
Phase 3 | |
| Terminated |
NCT03836872 -
Acupuncture for Joint Symptoms in Patients With Breast Cancer
|
N/A | |
| Completed |
NCT01671319 -
Dose Dense TC + Pegfilgrastim Support for Breast Cancer
|
Phase 2 | |
| Not yet recruiting |
NCT06092892 -
IIT2023-09-Chung-UpfrontTAD: Upfront TAD/SNB in Patients With Breast Cancer With Nodal Metastases
|
Phase 2 | |
| Recruiting |
NCT05586256 -
Ultra-hypofractionated Radiotherapy in Breast Cancer Patients
|
||
| Not yet recruiting |
NCT03153631 -
Female Sexual Dysfunction in Breast Cancer Patients
|
N/A | |
| Active, not recruiting |
NCT03059875 -
Place of Comprehensive Geriatric Assessment in Patients ≥ 75 Years Care, With Breast Cancer, After Screening With FOG (Oncology Geriatric Filter)
|
N/A | |
| Active, not recruiting |
NCT02088710 -
Expectations and Side Effects of Endocrine Therapy in Women With Breast Cancer
|
N/A | |
| Terminated |
NCT01083641 -
Estrogen for Triple Negative Breast Cancer
|
Phase 2 | |
| Recruiting |
NCT05374161 -
An Intervention for Female Breast CANcer: Acceptance and Commitment Therapy (I-CAN-ACT) for Depression and Physical Pain
|
N/A | |
| Recruiting |
NCT05438810 -
This is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of FCN-437c in Combination With Fluvestrant ± Goseraline Versus Placebo Combined With Fulvestrant ± Goserelin in Women With HR+ and HER2- Advanced Breast Cancer.
|
Phase 3 |